Isracann Biosciences EBITDA vs. Current Ratio
Based on Isracann Biosciences' profitability indicators, Isracann Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Isracann Biosciences' ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis.
For Isracann Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Isracann Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Isracann Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Isracann Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Isracann Biosciences over time as well as its relative position and ranking within its peers.
Isracann |
Isracann Biosciences Current Ratio vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Isracann Biosciences's current stock value. Our valuation model uses many indicators to compare Isracann Biosciences value to that of its competitors to determine the firm's financial worth. Isracann Biosciences is rated below average in ebitda category among its peers. It is rated below average in current ratio category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Isracann Biosciences' earnings, one of the primary drivers of an investment's value.Isracann Current Ratio vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Isracann Biosciences |
| = | (4.64 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Isracann Biosciences |
| = | 0.76 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Isracann Current Ratio Comparison
Isracann Biosciences is currently under evaluation in current ratio category among its peers.
Isracann Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Isracann Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Isracann Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Isracann Biosciences' change in net profit over the period of time. It can combine multiple indicators of Isracann Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States.
Isracann Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Isracann Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Isracann Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Isracann Biosciences' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Isracann Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Use Investing Themes to Complement your Isracann Biosciences position
In addition to having Isracann Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Isracann Pink Sheet
To fully project Isracann Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Isracann Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Isracann Biosciences' income statement, its balance sheet, and the statement of cash flows.